Metabolism of the platelet-activating factor antagonist (±)-trans-2-(3′-methoxy-5′-methylsulphonyl-4′-propoxyphenyl)-5-(3″, 4″,5″-trimethoxyphenyl)tetrahydrofuran (L-659,989) in rhesus monkeys

References

• Arnoux B. F., Duval D., Benveniste J. Release of platelet-activating factor (PAF-acether) from alveolar macrophages by calcium ionophore A23187 and phagocytosis. European Journal of Clinical Investigation 1980; 10: 437–441
   PubMed Web of Science ®Google Scholar
• Benveniste J., Henson P. M., Cochrane C. G. Leukocyte-dependent histamine release from rabbit platelets. Journal of Experimental Medicine 1972; 136: 1356–1377
   PubMed Web of Science ®Google Scholar
• Biftu T., Gamble N. F., Doebber T., Hwang S.-B., Shen T.-Y., Snyder J., Springer J. P., Stevenson R. Conformation and activity of tetrahydrofuran lignans and analogues as platelet activating factor antagonists. Journal of Medicinal Chemistry 1986; 29: 1917–1921
   PubMedGoogle Scholar
• Blank M. L., Snyder F., Byers L. W., Brooks B., Muirhead E. E. Antihypertensive activity of an alkyl ether analog of phosphatidylcholine. Biochemical and Biophysical Research Communications 1979; 90: 1194–1200
   PubMed Web of Science ®Google Scholar
• Blank M. L., Lee T.-C., Cress E. A., Malone B., Fitzgerald V., Snyder F. Conversion of 1-alkyl-2-acetyl-sn-glycerols to platelet activating factor and related phospholipids by rabbits platelets. Biochemical and Biophysical Research Communications 1984; 124: 156–163
   PubMedGoogle Scholar
• Braquet P. G., Spinnewyn B., Braquet M., Bourgian R. H., Taylor J. E., Etienne A., Drieu K. BN 52021 and related compounds: a new series of highly specific PAF-acether receptor antagonists isolated from Ginkgo biloba L. K. Ketsueki to Myakkan 1985; 16: 558–572
   Google Scholar
• Doebber T. W., Wu M. S., Shen T. Y. Platelet activating factor intravenous infusion in rats stimulates vascular lysosomal hydrolase secretion independent of blood neutrophils. Biochemical and Biophysical Research Communications 1984; 125: 980–987
   PubMed Web of Science ®Google Scholar
• Feuerstein G., Lux W. E., Jr, Snyder F., Ezra D., Faden A. I. Hypotension produced by platelet-activating factor is reversed by thryotropin-releasing hormone. Circulatory Shock 1984; 13: 255–260
   PubMedGoogle Scholar
• Harris R. A., Clay K., Murphy R., Henson P. Effects of PAF and related lipids on membrane physical properties. Federation Proceedings 1985; 44: 858, abstr
   Google Scholar
• Hwang S.-B., Lam M.-H., Biftu T., Beattie T. R., Shen T.-Y. Trans-2, 5-bis(3,4,5-timethoxyphenyl)tetrahydrofuran. An orally active specific and competitive receptor antagonist of platelet activating factor. Journal of Biological Chemistry 1985; 260: 15639–15645
   PubMedGoogle Scholar
• Hwang S.-B., Lam M.-H., Alberts A. W., Bugianesi R. L., Chabala J. C., Ponpipom M. M. Biochemical and pharmacological characterization of L-659,989: an extremely potent, selective and competitive receptor antagonist of platelet-activating factor. Journal of Pharmacology and Experimental Therapeutics 1988; 246: 534–541
   PubMed Web of Science ®Google Scholar
• Lee T.-C., Lenihan D. J., Malone B., Roddy L. L., Wasserman S. I. Increased biosynthesis of platelet-activating factor in activated human eosinophils. Journal of Biological Chemistry 1984; 259: 5526–5530
   PubMed Web of Science ®Google Scholar
• Mazzoni L., Morley J., Page C. P., Sanjar S. Induction of airway hyper-reactivity by platelet activating factor in the guinea-pig. Journal of Physiology (London) 1985; 365: 107P
   Web of Science ®Google Scholar
• Muirhead E. E., Byer L. W., Desiderio D., Smith K. A., Prewitt R. L., Brooks B. Alkyl ethyl analogs of phosphatidylcholine are orally active in hypertensive rabbits. Hypertension (Dallas) 1981; 3(Suppl. 1)107–111
   Google Scholar
• Otsuka A., Masugi F., Ogihara T., Saeki S., Nagano M., Koyama Y., Tabuchi Y., Kumahara Y. Hypotensive mechanism of acetyl glyceryl ether phosphorylcholine (AGEPC) in dogs. Effects on hemodynamics and humoral factors. Prostaglandins Leukotrienes and Medicine 1985; 19: 25–35
   PubMedGoogle Scholar
• Pinckard R. N., Ludwig J. C., McManus L. M. Modulation of the synthesis and release of platelet-activating factor (PAF) from human neutrophils (PMN) by albumin. Federation Proceedings 1983; 42: 692, abstr
   Google Scholar
• Ponpipom M. M., Bugianesi R. L., Brooker D. R., Yue B.-Z., Hwang S.-B., Shen T.-Y. Structure-activity relationships of kadsurenone analogues. Journal of Medicinal Chemistry 1987; 30: 136–142
   PubMedGoogle Scholar
• Ponpipom M. M., Hwang S.-B., Doebber T. W., Acton J. J., Alberts A. W., Biftu T., Brooker D. R., Bugianesi R. L., Chabala J. C., Gamble N. L., Graham D. W., Lam M.-H., Wu M. S. Trans-2-(3-methoxy-5-methylsulphonyl-4-propoxyphenyl)-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran (L-659, 989), A novel, potent PAF receptor antagonst. Biochemical and Biophysical Research Communications 1988a; 150: 1213–1220
   PubMed Web of Science ®Google Scholar
• Ponpipom M. M., Bugianesi R. L., Chabala J. C. Enamioselective cyclization of chiral butane-1,4-diols to chiral tetrahydrofurans: synthesis of chiral trans-2-(3-methoxy-5-methylsulphonyl-4-prcpoxyphenyl)-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran (L-659,989), a potent PAF-receptor anatagonst. Tetrahedron Letters 1988b; 29: 6211–6214
   Web of Science ®Google Scholar
• Rosam A.-C., Wallace J. L., Whittle B. J. R. Potent ulcerogenic actions of platelet-activating factor on the stomach. Nature (London) 1986; 319: 54–56
   PubMed Web of Science ®Google Scholar
• Shen T. Y., Hwang S.-B., Chang M. N., Doebber T. W., Lam M.-H., Wu M. S., Wang X., Han G. Q., Li R. Z. Characterization of a platelet-activating factor receptor antagonist isolated from haitenteng (Piper fatukadsura): specific inhibition of in vitro and in vivo platelet-activating factor-induced effects. Proceedings of the National Academy of Sciences of the United States of America 1985; 82: 672–676
   PubMedGoogle Scholar
• Terashita Z.-I., Tsushima S., Yoshioka Y., Nomura H., Inada Y., Nishikawa K. CV-3988—a specific antagonist of platelet activiating factor (PAF). Life Sciences 1983; 32: 1975–1982
   PubMed Web of Science ®Google Scholar
• Wu M. S., Biftu T., Doebber T. W. Inhibition of the platelet activating factor (PAF)-induced in vivo responses in rats by trans-2,2-(3,4,5-trimethoxyphenyl)tetrahydrofuran (L-652,731), a PAF receptor antagonist. Journal of Pharmacology and Experimental Therapeutics 1986; 239: 841–845
   PubMedGoogle Scholar
• Wykle R. L., Miller C. H., Lewis J. C., Schmitt J. D., Smith J. A., Surles J. R., Piantaoosi C., O'Flaherty J. T. Stereospecific activity of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine and comparison of analogs in the degranulation of platelets and neutrophils. Biochemical and Biophysical Research Communications 1981; 100: 1651–1658
   PubMed Web of Science ®Google Scholar
• Yeh K. C., Kwan K. C. A comparison of numerical integrating algorithms by Trapezoidal, Lagrange, and Spline approximation. Journal of Pharmacokinetics and Biopharmaceutics 1978; 6: 79–98
   PubMedGoogle Scholar
• Yeh K. C., Winchell G. A., Barrett J. S. A program for calculating AUC in pharmacokinetics using stable piecewise cubic polynomial interpolants. The Japanese-United States Congress of Pharmaceutical Sciences 1987; S104
   Google Scholar